Recent 8-K filings for PBH

• May 13, 2026, 4:35 PM ET M&A materiality 0.75 neutral item 1.01item 2.02item 7.01item 9.01

  Prestige Consumer reports FY26 adj EPS $4.38; acquires LaCorium Health for $150M

  FY26 revenue $1,088.7M (-4.3% YoY); adjusted diluted EPS $4.38 vs $4.52 prior year.

• March 20, 2026, 7:59 PM ET M&A materiality 0.85 positive item 1.01item 7.01item 8.01item 9.01 ◈ Material Agreements

  Prestige Consumer Healthcare to acquire Breathe Right brand portfolio for $1.045B

  Acquisition includes Breathe Right, Dimetapp, Anbesol brands; trailing revenue $200M, EBITDA $95M.

• February 5, 2026, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Prestige Q3 revenue $283.4M, down 2.4% YoY; adjusted EPS $1.14 vs $1.22

  GAAP diluted EPS $0.97; adjusted diluted EPS $1.14 (down from $1.22); net income $46.7M.

• November 6, 2025, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01

  Prestige Consumer Q2 adj EPS $1.07 beats prior year; raises FY adj EPS guidance to $4.54-$4.58

  Q2 revenue $274.1M (-3.4% YoY); diluted EPS $0.86 vs $1.09; adjusted EPS $1.07.

• August 7, 2025, 7:59 PM ET earnings materiality 0.85 negative item 1.01item 2.02item 7.01item 9.01

  Prestige Q1 revenue down 6.6%, misses; acquires Pillar5 for CAD 150M, cuts FY26 outlook

  Revenue $249.5M (-6.6% YoY); diluted EPS $0.95 ($0.90 adjusted).

• May 8, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Prestige Q4 revenue $296.5M, adj EPS $1.32; FY25 adj EPS $4.52; FY26 outlook $4.70-4.82

  Q4 revenue $296.5M (+7.0% YoY, organic +7.9%); diluted EPS $1.00 GAAP, adjusted $1.32 (vs $1.02 prior year).

• February 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Prestige Q3 FY2025 EPS $1.22 (+15% YoY); raises FY25 adjusted EPS outlook to ~$4.50

  Q3 revenues $290.3M (+2.7% YoY); record quarterly sales and EPS.

• January 6, 2025, 6:59 PM ET leadership materiality 0.55 neutral item 5.02item 9.01 ◈ executive_change

  Prestige Consumer Healthcare expands CFO Christine Sacco's role to include COO, effective immediately

  Christine Sacco, CFO since 2016, appointed COO/CFO effective Jan 6, 2025; will oversee supply chain.

• November 7, 2024, 6:59 PM ET earnings materiality 0.60 positive item 2.02item 7.01item 9.01

  Prestige Consumer Healthcare Q2 revenue $283.8M, diluted EPS $1.09; reaffirms FY2025 outlook

  Revenue $283.8M (-0.9% YoY) slightly ahead of expectations; diluted EPS $1.09 vs $1.07 prior year.

• August 8, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01

  Prestige Consumer Q1 revenue $267.1M beats expectations; reaffirms FY2025 outlook

  Q1 GAAP EPS $0.98, adjusted EPS $0.90; revenue down 4.4% YoY but ahead of internal plan.

• May 14, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 8.01item 9.01 ◈ Earnings Releases ×2

  Prestige Consumer Q4 revenue down 2.9%; adj. EPS $1.02; $300M buyback; FY2025 EPS guidance $4.40-$4.46

  Q4 revenue $277.0M (-2.9% ex-FX); non-GAAP adj. diluted EPS $1.02 vs $1.07 prior year.

• May 8, 2024, 7:59 PM ET leadership materiality 0.15 neutral item 5.02 ◈ executive_change

  Prestige Consumer Healthcare elects John F. Kelly, former Pfizer VP, to Board

  John F. Kelly, former Vice President Quality Operations and EHS at Pfizer, elected to PBH Board on May 7, 2024.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

6 positive 2 negative 4 neutral

source · PBH on sec.gov